Belvedere Trading
SCPH

Belvedere Trading’s scPharmaceuticals SCPH Stock Holding History

Belvedere Trading’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-120,706
Closed -$661K – 1202
2022
Q3 		$661K Sell
120,706
-118,513
-50% -$633K 0.02% 57
2022
Q2 		$1.27M Buy
239,219
+78,337
+49% +$388K 0.04% 37
2022
Q1 		$822K Buy
+160,882
New +$790K 0.02% 65

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Belvedere Trading's SCPH Position: Q4 2022 in Review

Belvedere Trading sold out of scPharmaceuticals (SCPH) in Q4 2022, closing a stake of 120,706 shares — an estimated $661K sold.

Belvedere Trading first reported a position in SCPH in Q1 2022 and held it in 3 quarters. The position peaked at $1.27M in Q2 2022. 58 funds tracked by Wall St. Rank hold SCPH as of Q4 2022.

  • Belvedere Trading reported no remaining scPharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Belvedere Trading sold 120,706 scPharmaceuticals shares in Q4 2022, an estimated $661K.
  • Belvedere Trading first reported a position in scPharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Belvedere Trading's scPharmaceuticals position peaked at $1.27M in Q2 2022.
  • 58 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2022.

Based on Belvedere Trading's 13F filing for Q4 2022, filed 15 Feb 2023.